🔬 Developers must learn from other industries to successfully transition from lab-scale to clinical-scale production.
🏭 Lack of scale-up expertise is a major challenge for CGT manufacturers.
⚙️ Industries like automotive and medical devices have mastered effective scaleup methods.
💡 CGT companies need to recognize the importance of efficient manufacturing principles and methods.
💰 Venture-backed CGT developers often focus on early-phase development, neglecting late-stage trials and commercialization.
🤝 Hiring people with deep knowledge and experience in manufacturing at scale is crucial.
🤖 Automation can solve many challenges in making cell and gene therapies, but expertise is necessary.
🌱 When automation is applied properly, CGT manufacturing will resemble producing household goods or commonly used drugs.
Introduction:
Cell and gene therapy manufacturers often struggle to scale up their production from lab-scale to clinical-scale. This is due to a lack of expertise in scaling up operations. Automation can help address this challenge, but it requires knowledge from other industries to be effectively applied in the cell and gene therapy field.
- CGT manufacturers face the challenge of quickly creating a scalable manufacturing operation as clinical patient demand increases. However, they lack the necessary knowledge and understanding of efficient manufacturing principles.
- Industries like automotive and medical device manufacturing have developed effective systems and processes for scaling up production, unlike the CGT industry.
- Many CGT developers are venture capital backed, which can lead to a focus on early-phase development rather than late-stage trials and commercialization.
- Some venture-funded CGT companies fail to recognize the importance of hiring people with deep manufacturing expertise and experience.
- Automation can solve many of the challenges faced in cell and gene therapy manufacturing, but it requires proper application and expertise from other industries.
Conclusion:
Scaling up cell and gene therapy manufacturing requires automation and knowledge from other industries. Developers need to learn from sectors like automotive and medical device manufacturing to establish scalable manufacturing operations. Additionally, venture-backed CGT companies should recognize the value of hiring people with expertise in manufacturing at scale. Overall, the successful scale-up of cell and gene therapies relies on automation and cross-industry knowledge.
